- Home
- WATT vs EVOK Comparison
WATT vs EVOK Comparison
Compare WATT & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- EVOK
- Stock Information
- Founded
- WATT 2012
- EVOK 2007
- Country
- WATT United States
- EVOK United States
- Employees
- WATT N/A
- EVOK N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- EVOK Health Care
- Exchange
- WATT Nasdaq
- EVOK Nasdaq
- Market Cap
- WATT 3.9M
- EVOK 4.2M
- IPO Year
- WATT 2014
- EVOK 2013
- Fundamental
- Price
- WATT $0.61
- EVOK $5.40
- Analyst Decision
- WATT Strong Buy
- EVOK
- Analyst Count
- WATT 2
- EVOK 0
- Target Price
- WATT $2.25
- EVOK N/A
- AVG Volume (30 Days)
- WATT 133.2K
- EVOK 29.3K
- Earning Date
- WATT 11-07-2024
- EVOK 11-07-2024
- Dividend Yield
- WATT N/A
- EVOK N/A
- EPS Growth
- WATT N/A
- EVOK N/A
- EPS
- WATT N/A
- EVOK N/A
- Revenue
- WATT $370,184.00
- EVOK $7,525,709.00
- Revenue This Year
- WATT $95.75
- EVOK $124.10
- Revenue Next Year
- WATT $834.07
- EVOK $75.70
- P/E Ratio
- WATT N/A
- EVOK N/A
- Revenue Growth
- WATT N/A
- EVOK 110.79
- 52 Week Low
- WATT $0.54
- EVOK $3.54
- 52 Week High
- WATT $2.75
- EVOK $17.88
- Technical
- Relative Strength Index (RSI)
- WATT 48.13
- EVOK 57.84
- Support Level
- WATT $0.56
- EVOK $5.14
- Resistance Level
- WATT $0.61
- EVOK $5.61
- Average True Range (ATR)
- WATT 0.04
- EVOK 0.43
- MACD
- WATT 0.01
- EVOK 0.02
- Stochastic Oscillator
- WATT 69.60
- EVOK 49.58
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.